IPP Bureau
Pulmatrix resolves dispute with Cipla
By IPP Bureau - November 10, 2021
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
India Pharmaceutical Market grows 5% in October 2021
By IPP Bureau - November 10, 2021
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22
By IPP Bureau - November 10, 2021
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Zydus Cadila receives approval for glycopyrrolate injection
By IPP Bureau - November 10, 2021
Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated
Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
By IPP Bureau - November 10, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Intuitive India familiarises surgeons on Robotic-Assisted Surgery
By IPP Bureau - November 10, 2021
The workshop had been organized by the department of surgery at Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University (AMU), along with the Association of Surgeons of Aligarh (ASA)
Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
By IPP Bureau - November 10, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Wockhardt PAT at Rs 33.53 cr. in Q2FY22
By IPP Bureau - November 09, 2021
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures
By IPP Bureau - November 09, 2021
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively
By IPP Bureau - November 09, 2021
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
EVA Pharma to open vaccine manufacturing facility in Cairo
By IPP Bureau - November 09, 2021
The new facility will provide an important boost to vaccine capacity in Africa
Sanofi to invest up to US $ 60 million in Gyroscope
By IPP Bureau - November 09, 2021
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
First clinical use of Lucent 3D Lumber successful
By IPP Bureau - November 09, 2021
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
Amneal Pharmaceuticals acquires Puniska Healthcare for Rs 700 crore
By IPP Bureau - November 09, 2021
The company has operations in North America, Asia, and Europe,
Pfizer’s Covid-19 drug a potential game changer
By IPP Bureau - November 08, 2021
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
